Sight Sciences
Developer of glaucoma implants for the treatment of irreversible blindness.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 77 % | 46 % | 14 % | (1 %) | (6 %) | 11 % | 15 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (119 %) | (115 %) | (61 %) | (62 %) | (54 %) | (41 %) | (32 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (129 %) | (121 %) | (69 %) | (64 %) | (73 %) | (61 %) | (46 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 32 % | 32 % | 22 % | 23 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Sight Sciences, Inc. operates as a medical device company focused on the ophthalmology sector, specifically targeting the underlying causes of glaucoma and dry eye disease. Incorporated in 2011 and headquartered in Menlo Park, California, the company was founded by brothers Paul Badawi, who serves as Chief Executive Officer, and Dr. David Badawi, the Chief Technology Officer. The founders established the company to address unmet needs within eye care. Their journey culminated in significant corporate milestones, including a successful initial public offering on the Nasdaq exchange in July 2021 under the ticker 'SGHT', which raised approximately $276 million in gross proceeds.
The company's business model is centered on the development and commercialization of proprietary medical devices, which it sells directly to ophthalmologists and optometrists. Revenue is generated through these direct sales. Sight Sciences' product portfolio is divided into two main segments: Surgical Glaucoma and Dry Eye. The Surgical Glaucoma segment, which accounted for the majority of the company's revenue, features the OMNI Surgical System. This system is a minimally invasive glaucoma surgery (MIGS) device used to reduce intraocular pressure in adult patients with primary open-angle glaucoma by facilitating canaloplasty and trabeculotomy through a single corneal incision. The OMNI system is designed to address all three known points of resistance in the eye's aqueous outflow system.
In the Dry Eye segment, the company offers the TearCare System. This system is designed for the application of localized heat to the eyelids to treat meibomian gland dysfunction (MGD), a leading cause of evaporative dry eye disease. The TearCare device is a wearable, open-eye technology that allows the patient's eyes to remain open and blinking during the procedure, while soft, flexible thermal units conform to the eyelids to deliver a therapeutic level of heat. The company has pursued a strategy of conducting robust clinical trials to demonstrate the efficacy of its products and to support efforts in securing favorable reimbursement from third-party payors.
Keywords: ophthalmic medical devices, glaucoma treatment, dry eye disease, OMNI Surgical System, TearCare System, minimally invasive glaucoma surgery, MIGS, meibomian gland dysfunction, Paul Badawi, David Badawi, interventional ophthalmology, canaloplasty, trabeculotomy, eye care technology, SGHT, intraocular pressure, vision health, surgical devices, evaporative dry eye, therapeutic heat technology